Breaking News, Financial News

Financial Reports: Alexion

Soliris continues to rise

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alexion 1Q13 1Q Revenues: $339 million (+38%) 1Q Earnings: $82 million (+81%) Comments: Sales of Soliris climbed 38% to $339 million, adding patients for both paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) indications. R&D expenses climbed 64% to $75 million as the company advanced five clinical programs, including one with Soliris....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters